For a more technical dive into startups that have been chugging along with AI in pathology for ~decade, check out this:

https://www.owlposting.com/p/what-happened-to-pathology-ai-c...

> One pathology AI founder told me that it wasn’t hospitals or diagnostic labs that showed the most promise. It was R&D groups within Big Pharma. Those scientists and executives wanted new tooling. They were often sitting on massive internal datasets, had real budget allocated to experimental tech, and — critically — had a clear ROI if your model helped shave months off a study or more precisely target the right patient cohort. Most importantly, pharma didn’t care as much about the regulatory headaches, as they weren’t using your model to diagnose patients